- Home
- AMZE vs BIAF Comparison
AMZE vs BIAF Comparison
Compare AMZE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | BIAF |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | 28 | 57 |
| Industry | Beverages (Production/Distribution) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AMZE | BIAF |
|---|---|---|
| Price | $0.12 | $0.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 418.7K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,986.62 | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.23 |
| 52 Week High | $11.70 | $13.50 |
Technical Indicators
Market Signals| Indicator | AMZE | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 28.56 |
| Support Level | $0.12 | $0.78 |
| Resistance Level | $0.20 | $1.45 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 16.80 | 8.92 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a technology-enabled, creator-powered commerce platform that enables creators, brands, and consumers to transact at scale. The Company provides infrastructure for creators and brands to design, launch, market, and fulfill products. The Company operates in two segments: E-commerce / Subscriptions, which includes the Amaze platform and creator commerce operations supporting product sales, subscription offerings, and digital content delivery; and Wine Products, which includes the sale of Fresh Vine wines through wholesale and direct-to-consumer channels across the United States and Puerto Rico.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.